71 related articles for article (PubMed ID: 9012924)
1. High-dose chemotherapy with autologous stem cell transplantation is feasible and safe in a regional hospital. A 6-year experience in southern Switzerland.
Regazzoni S; Marini G; Grob A; Pedrazzini A; Goldhirsch A; Castelli D; Cavalli F; Ghielmini M
Bone Marrow Transplant; 1997 Jan; 19(1):3-7. PubMed ID: 9012924
[TBL] [Abstract][Full Text] [Related]
2. [High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich].
Jost LM; Honegger HP; Stahel RA
Schweiz Med Wochenschr; 2000 Jan; 130(3):60-9. PubMed ID: 10683881
[TBL] [Abstract][Full Text] [Related]
3. Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation.
Schetelig J; Fetscher S; Reichle A; Berdel WE; Beguin Y; Brunet S; Caballero D; Majolino I; Hagberg H; Johnsen HE; Kimby E; Montserrat E; Stewart D; Copplestone A; Rösler W; Pavel J; Kingreen D; Siegert W
Haematologica; 2003 Nov; 88(11):1272-8. PubMed ID: 14607756
[TBL] [Abstract][Full Text] [Related]
4. Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response.
Ganguly S; Divine CL; Deauna-Limayo D; Bodensteiner DC; Cook JD; Lewis JN; Skikne BS
Ann Hematol; 2005 Aug; 84(8):526-31. PubMed ID: 15915350
[TBL] [Abstract][Full Text] [Related]
5. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.
Steingrimsdottir H; Gruber A; Björkholm M; Svensson A; Hansson M
Haematologica; 2000 Aug; 85(8):832-8. PubMed ID: 10942930
[TBL] [Abstract][Full Text] [Related]
6. [Treatment outcome and prognosis of autologous hematopoietic stem cell transplantation combined with high dose radiotherapy/chemotherapy in 22 patients with nasal NK/T cell lymphoma].
Cui XZ; Wang HQ; Liu XM; Zhang HL; Li W
Zhonghua Xue Ye Xue Za Zhi; 2007 Sep; 28(9):609-11. PubMed ID: 18246818
[TBL] [Abstract][Full Text] [Related]
7. Long-term haematological recovery following high-dose chemotherapy with autologous bone marrow transplantation or peripheral stem cell transplantation in patients with solid tumours.
Nieboer P; de Vries EG; Mulder NH; Sleijfer DT; Willemse PH; Hospers GA; Gietema JA; Sluiter WJ; van Der Graaf WT
Bone Marrow Transplant; 2001 May; 27(9):959-66. PubMed ID: 11436106
[TBL] [Abstract][Full Text] [Related]
8. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
[TBL] [Abstract][Full Text] [Related]
9. High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients.
Durando X; Lemaire JJ; Tortochaux J; Van-Praagh I; Kwiatkowski F; Vincent C; Bailly C; Verrelle P; Irthum B; Chazal J; Bay JO
Bone Marrow Transplant; 2003 Apr; 31(7):559-64. PubMed ID: 12692621
[TBL] [Abstract][Full Text] [Related]
10. Autologous stem cell transplantation for high-risk Hodgkin's disease: improvement over time and impact of conditioning regimen.
Subirà M; Sureda A; Martino R; García J; Altés A; Canals C; Domingo-Albós A; Brunet S; Sierra J
Haematologica; 2000 Feb; 85(2):167-72. PubMed ID: 10681724
[TBL] [Abstract][Full Text] [Related]
11. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma.
Stockerl-Goldstein KE; Horning SJ; Negrin RS; Chao NJ; Hu WW; Long GD; Hoppe RT; Amylon MD; Brown BW; Wong RM; Blume KG
Biol Blood Marrow Transplant; 1996 May; 2(2):76-85. PubMed ID: 9118302
[TBL] [Abstract][Full Text] [Related]
12. High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin.
Stein RS; Greer JP; Goodman S; Kallianpur A; Ahmed MS; Wolff SN
Bone Marrow Transplant; 1999 Feb; 23(3):227-33. PubMed ID: 10084253
[TBL] [Abstract][Full Text] [Related]
13. [High-dose chemotherapy with autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in complete response as consolidation therapy, second report].
Yamane T; Hirose A; Nakajima Y; Nakane T; Koh H; Takeoka Y; Nakamae M; Yamamura R; Nakamae H; Nakao Y; Mugitani A; Yagi T; Teshima H; Hino M
Gan To Kagaku Ryoho; 2006 Feb; 33(2):193-8. PubMed ID: 16484855
[TBL] [Abstract][Full Text] [Related]
14. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience.
Rodríguez J; Conde E; Gutiérrez A; Arranz R; Gandarillas M; Leon A; Ojanguren J; Sureda A; Carrera D; Bendandi M; Moraleda J; Ribera JM; Albo C; Morales A; García JC; Fernández P; Cañigral G; Bergua J; Caballero MD;
Eur J Haematol; 2007 Apr; 78(4):290-6. PubMed ID: 17378891
[TBL] [Abstract][Full Text] [Related]
15. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
[TBL] [Abstract][Full Text] [Related]
16. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D
Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
[TBL] [Abstract][Full Text] [Related]
18. Factors influencing haemopoietic recovery following chemotherapy-mobilised autologous peripheral blood progenitor cell transplantation for haematological malignancies: a retrospective analysis of a 10-year single institution experience.
Lowenthal RM; Fabères C; Marit G; Boiron JM; Cony-Makhoul P; Pigneux A; Agape P; Vezon G; Bouzgarou R; Dazey B; Fizet D; Bernard P; Lacombe F; Reiffers J
Bone Marrow Transplant; 1998 Oct; 22(8):763-70. PubMed ID: 9827973
[TBL] [Abstract][Full Text] [Related]
19. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
20. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells.
Visani G; Lemoli R; Tosi P; Martinelli G; Testoni N; Ricci P; Motta M; Gherlinzoni F; Leopardi G; Pastano R; Rizzi S; Piccaluga P; Isidori A; Tura S
Bone Marrow Transplant; 1999 Sep; 24(5):467-72. PubMed ID: 10482929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
